B Braun Medical recalled 10,536 Anesthesia IV Sets on October 29, 2025. The recall stems from a risk of medication backflow between IV containers. Healthcare providers must stop using the product immediately to prevent potential harm.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact B Braun Medical Inc or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled Anesthesia IV Set is catalog number 490472 and has a primary UDI-DI of 04046964958878. The product was distributed worldwide, including the US, Canada, Germany, Guatemala, and Singapore.
The Anesthesia IV Set poses a high risk of backflow of medication from secondary IV containers into primary IV containers. This defect could lead to incorrect medication dosing and potential patient harm.
As of the recall date, there are no reported injuries or deaths associated with this product. However, the risk of medication errors remains a serious concern.
Stop using the Anesthesia IV Set immediately. Follow the recall instructions provided by B Braun Medical Inc. Contact your healthcare provider for guidance.
For further information, contact B Braun Medical Inc. or visit their website. Recall notifications are being sent via letter.
Get instant alerts for recalls that affect you. Free forever.
Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Software anomaly in the patient positioning system may result in positional discrepancy.
Software anomaly in the patient positioning system may result in positional discrepancy.
Customer complaints report low to no recovery of Campylobacter Jejuni ATCC 33291 on identified lot of medium.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.